Accelerate Diagnostics announces FDA clearance of Accelerate Arc system

Accelerate Diagnostics announced that the U.S. Food and Drug Administration, FDA, has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker’s MALDI Biotyper CA System, MBT-CA System, and MBT-CA Sepsityper software extension. “The FDA Clearance of the Accelerate Arc system marks the beginning of an exciting journey in our broader innovation roadmap. Together with the Accelerate WAVE system we are positioned to empower laboratories to deliver faster, more actionable results to clinicians, ultimately enhancing patient care and outcomes.” said Jack Phillips, President and CEO of Accelerate Diagnostics.